Snapdeal's AceVector IPO: Fresh Issue vs OFS Explained

Remember Snapdeal? The pink-logo shopping app that was, for a hot minute around 2015, the scrappy Indian answer to Amazon and Flipkart, before it quietly faded from most people's home screens? Its parent company, AceVector, is about to list on the stock exchange. And buried in its IPO papers is a detail far more useful than any grey-market-premium number: exactly where the ₹420 crore is actually going.

AceVector's IPO opens September 25 and closes September 29, 2026, priced at ₹30–32 a share, valuing the company at roughly ₹1,750 crore. Shares are expected to list on the BSE and NSE around October 5. But before anyone asks "should I apply," there's a more useful question: whose pockets is this money actually going into?

The number that matters more than the price band

Every IPO prospectus splits the raise into two very different buckets, and most first-time investors skim right past this part.

• Fresh issue — new shares the company creates and sells, with the money going straight into the company's own bank account to fund growth, pay debt, or invest in the business.
• Offer for Sale (OFS) — existing shares that early investors, founders, or employees are simply selling to the public. The company gets zero rupees from this; the money goes entirely to the sellers.

AceVector's ₹420 crore IPO breaks down as roughly ₹287 crore in fresh issue and ₹133 crore in OFS. In plain terms: about two-thirds of the money you'd invest goes to build the actual business, and about one-third goes straight into the pockets of existing shareholders who are partially cashing out.

Who's selling, and why it's worth noticing

The OFS sellers in AceVector's IPO include SoftBank's Starfish entity and Nexus Venture Partners, alongside several other early investors and individuals. This isn't unusual — early investors in any startup eventually look for an exit, and an IPO is one of the cleanest ways to get it. But it's a useful data point: when a chunk of an IPO is existing investors taking money off the table rather than the company raising growth capital, it's worth asking why they're choosing to sell now, at this valuation, rather than holding on.

Where AceVector says the fresh money is going

According to the company's filings, a large share of the fresh issue proceeds — around ₹132 crore — is earmarked for marketing and business promotion of its marketplace business, with another roughly ₹50 crore going toward technology infrastructure. That's worth sitting with: this isn't primarily a factory-expansion or debt-repayment story, it's largely a "spend more to acquire customers and compete" story, in a marketplace segment that's seen brutal, cash-burning competition from far better-funded players for a decade.

Why grey-market premium is a bad reason to apply

Every IPO week, the same question floods group chats: "GMP kitna hai?" The grey market premium is an unregulated, informal, pre-listing indicator of demand — and it has a well-documented habit of swinging wildly, being manipulated by a small pool of operators, and telling you almost nothing about whether the underlying business is actually a good long-term hold. A strong GMP can evaporate by listing day; a weak one can flip positive. Basing a real investment decision on it is closer to reading tea leaves than to analysis.

The fresh-issue-vs-OFS split, on the other hand, is disclosed, audited, and tells you something durable: how much of your money is fuelling the company's future versus funding somebody else's exit.

The bigger pattern this fits into

AceVector is just one name in what's been an extraordinarily busy IPO season in 2026, with dozens of Indian companies rushing to list before regulatory approval windows close. In a rush like this, reading past the headline price band and GMP chatter — and actually checking the fresh issue-to-OFS ratio, the use-of-proceeds section, and who the selling shareholders are — is one of the simplest ways retail investors can tell a growth story apart from an exit story.

What this means for you

This isn't a verdict on whether AceVector is a good or bad investment — that depends on its financials, competitive position, and price, which deserve their own analysis. The point is narrower and more durable: for any IPO you're evaluating, spend two minutes checking how the raise splits between fresh issue and OFS before you spend two seconds checking the GMP. One of those numbers tells you something real about the company; the other mostly tells you what a small group of traders are betting on this week.

Snapdeal spent a decade fighting for relevance against much bigger rivals. Whether AceVector's public-market chapter goes any differently is genuinely an open question — but at least now you know how to read the paperwork instead of just the group chat.

Question for you: next time an IPO lands in your feed, will you check the fresh-issue-vs-OFS split before you check the GMP? This article is educational, based on public filings and news reports as of September 2026, and is not investment advice or a recommendation to apply for this or any IPO.